**Partial rescheduling of certain medical marijuana products to Schedule III occurred in April 2026, while the broader effort to move marijuana from Schedule I remains in the administrative process.** In April 2026, Acting Attorney General Todd Blanche issued a final order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective late April, following a Trump administration executive order directing expedited action. A separate expedited DEA hearing on broader rescheduling, including recreational cannabis, ran from June 29 to July 15, 2026, with post-hearing briefs submitted in mid-August. The administrative law judge’s recommendation is expected later in 2026 or into 2027, after which the DEA Administrator would issue a final rule subject to objections and potential litigation in the D.C. Circuit. Opposition from selected hearing participants, procedural timelines, and ongoing court challenges create uncertainty around completion dates, shaping trader assessments of near-term outcomes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$808,207 Vol.
Dec 31, 2026
September 30
7%
December 31
16%
$808,207 Vol.
September 30
$554 Vol.
7%
December 31
$198,082 Vol.
16%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain medical marijuana products to Schedule III occurred in April 2026, while the broader effort to move marijuana from Schedule I remains in the administrative process.**
In April 2026, Acting Attorney General Todd Blanche issued a final order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective late April, following a Trump administration executive order directing expedited action. A separate expedited DEA hearing on broader rescheduling, including recreational cannabis, ran from June 29 to July 15, 2026, with post-hearing briefs submitted in mid-August. The administrative law judge’s recommendation is expected later in 2026 or into 2027, after which the DEA Administrator would issue a final rule subject to objections and potential litigation in the D.C. Circuit.
Opposition from selected hearing participants, procedural timelines, and ongoing court challenges create uncertainty around completion dates, shaping trader assessments of near-term outcomes.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Volume
$808,207End Date
Jan 1, 2027Market Opened
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Partial rescheduling of certain medical marijuana products to Schedule III occurred in April 2026, while the broader effort to move marijuana from Schedule I remains in the administrative process.**
In April 2026, Acting Attorney General Todd Blanche issued a final order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective late April, following a Trump administration executive order directing expedited action. A separate expedited DEA hearing on broader rescheduling, including recreational cannabis, ran from June 29 to July 15, 2026, with post-hearing briefs submitted in mid-August. The administrative law judge’s recommendation is expected later in 2026 or into 2027, after which the DEA Administrator would issue a final rule subject to objections and potential litigation in the D.C. Circuit.
Opposition from selected hearing participants, procedural timelines, and ongoing court challenges create uncertainty around completion dates, shaping trader assessments of near-term outcomes.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$808,207End Date
Jan 1, 2027Market Opened
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Partial rescheduling of certain medical marijuana products to Schedule III occurred in April 2026, while the broader effort to move marijuana from Schedule I remains in the administrative process.** In April 2026, Acting Attorney General Todd Blanche issued a final order placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective late April, following a Trump administration executive order directing expedited action. A separate expedited DEA hearing on broader rescheduling, including recreational cannabis, ran from June 29 to July 15, 2026, with post-hearing briefs submitted in mid-August. The administrative law judge’s recommendation is expected later in 2026 or into 2027, after which the DEA Administrator would issue a final rule subject to objections and potential litigation in the D.C. Circuit. Opposition from selected hearing participants, procedural timelines, and ongoing court challenges create uncertainty around completion dates, shaping trader assessments of near-term outcomes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions